QualityStocksNewsBreaks – BridgeBio Pharma Inc. (NASDAQ: BBIO) Featured in Mizuho Securities Research Report
BridgeBio Pharma (NASDAQ: BBIO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are updating our model post the 1Q21 print. We removed patidegib, after the Ph3 trial failed to hit primary and secondary endpoints. We increased the PoS for encaleret in ADH1 from 20% to 60% after the recent encouraging Ph2 data in ADH1 (our notes: here and here) and start to assign some value to encaleret in the post-surgical hypoparathyroidism setting, moving PoS from 0% to 20%. No change to PT, still $86.”To request access to the full report,…
